Viridian Therapeutics, Inc.\DE (VRDN) Receivables - Net (2013 - 2024)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Receivables - Net of $14000.0 for Q3 2024, down 86.27% year-over-year from $102000.0 in Q4 2023, and down 86.27% quarter-over-quarter from $102000.0 in Q1 2024.
Viridian Therapeutics, Inc.\DE (VRDN) Receivables - Net (2013 - 2024) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Receivables - Net history runs 12 years deep, the most recent figure standing at $14000.0 for Q3 2024.
- In Q3 2024, Receivables - Net fell 86.27% year-over-year to $14000.0; the TTM figure through Sep 2024 stood at $14000.0 (down 86.27% YoY), while the FY2023 annual figure was $102000.0, changed 0.0% from the prior year.
- Receivables - Net for Q3 2024 stood at $14000.0, down from $102000.0 in the prior quarter.
- The five-year high for Receivables - Net was $1.0 million in Q3 2021, with the low at $4000.0 in Q1 2020.
- The 5-year median for Receivables - Net is $102000.0 (2022), against an average of $268333.3.
- The sharpest annual moves came in 2020 and 2021: Receivables - Net slumped 94.18% in 2020, then jumped 1654.39% in 2021.
- Viridian Therapeutics, Inc.\DE's Receivables - Net stood at $57000.0 in 2020, then surged by 691.23% to $451000.0 in 2021, then tumbled by 77.38% to $102000.0 in 2022, then changed by 0.0% to $102000.0 in 2023, then plunged by 86.27% to $14000.0 in 2024.
- Business Quant data shows VRDN's Receivables - Net at $14000.0 in Q3 2024, $102000.0 in Q1 2024, and $102000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 14,000.00 |
| Sep 30, 2024 | 14,000.00 |
| Mar 31, 2024 | 102,000.00 |
| Mar 31, 2024 | 102,000.00 |
| Dec 31, 2023 | 102,000.00 |
| Dec 31, 2023 | 102,000.00 |
| Sep 30, 2023 | 102,000.00 |
| Sep 30, 2023 | 102,000.00 |
| Jun 30, 2023 | 102,000.00 |
| Jun 30, 2023 | 102,000.00 |
| Mar 31, 2023 | 128,000.00 |
| Mar 31, 2023 | 128,000.00 |
| Dec 31, 2022 | 102,000.00 |
| Dec 31, 2022 | 102,000.00 |
| Sep 30, 2022 | 398,000.00 |
| Sep 30, 2022 | 398,000.00 |
| Jun 30, 2022 | 693,000.00 |
| Jun 30, 2022 | 693,000.00 |
| Mar 31, 2022 | 522,000.00 |
| Mar 31, 2022 | 522,000.00 |